A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Inclusion Criteria: * Physician-diagnosed asthma for at least 12 months prior to screening * Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen * Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period * Able to safely complete incremental exercise tolerance at screening * Pre-bronchodilator FEV1 of 40%-80% of predicted at screening * Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry * On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening * Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score * Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug. Exclusion Criteria: * Known history of anaphylaxis/hypersensitivity to omalizumab * Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening * Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 mon…